微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 43.54% | -23.69% | -14.97% | 87/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 51.21% | -14.45% | 0.2% | 77/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 51.1% | -18.05% | -5.53% | 76/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.1% | -16.88% | -5.2% | 70/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 57.06% | -9.08% | -4.68% | 58/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 59.86% | -7.13% | -4.01% | 55/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 62.36% | -3.89% | -4.19% | 48/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 65.08% | 3.02% | 3.7% | 42/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.76% | 5.84% | -2.62% | 46/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 64.45% | -4.21% | -0.66% | 50/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 64.88% | -4.28% | 2.7% | 48/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 63.17% | -4.83% | 6.53% | 51/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 59.3% | -7.08% | -11.87% | 60/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 67.29% | 6.29% | -0.73% | 48/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 67.78% | 4.12% | 2.11% | 40/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 66.38% | -0.41% | 4.02% | 45/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 63.82% | 0.91% | 0.81% | 40/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 63.31% | -16.42% | -2.76% | 54/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 65.1% | -17.03% | -2.33% | 41/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 66.65% | -16.55% | 5.4% | 38/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 63.24% | -20.5% | -16.51% | 42/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 75.74% | -9.62% | -3.46% | 25/158 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 78.46% | -6.71% | -1.77% | 16/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 79.87% | -5.09% | 0.41% | 16/158 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 79.55% | -5.12% | -5.08% | 14/158 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 83.8% | 12.98% | -0.36% | 16/158 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 84.1% | 22.25% | -0.06% | 10/158 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 84.15% | 34.34% | 0.38% | 11/158 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 83.84% | 34.45% | 13.03% | 11/158 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 74.17% | 19.87% | 7.82% | 21/158 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 68.8% | 2% | 9.83% | 20/158 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 62.64% | 2% | 1.23% | 27/158 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 61.88% | 0.14% | 0.14% | 30/158 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2015-12-31 | 61.79% | 6.87% | -0.9% | 24/158 | 45.97% | 贝达药业 | 95.58% | 行业排名> |
| 2015-03-31 | 62.36% | 2% | 7.84% | 16/158 | 43.46% | 贝达药业 | 95.89% | 行业排名> |